

Supplementary table 1: post-transplant overall survival, relapse free survival, and graft versus host disease-free relapse-free survival in 138 Mayo Clinic patients with chronic myelomonocytic leukemia who underwent allogeneic stem cell transplantation stratified by pre-transplant history of blast transformation.

Variables	Entire cohort (n=138)	Patients transplanted in chronic phase CMML (n=104)	Patients with pre- transplant history of blast transformation (n=34)	P-value HR (95% CI)
Post-transplant overall survival, Median (range), months	54 (0-212)	95 (2-212)	16 (0-204)	0.01 1.9 (1.2-3.2)
1 year, %	74	79	57	
3 years, %	57	62	39	
5 years, %	48	54	29	
Relapse-free survival, Median (range), months	34 (0-212)	54 (1-212)	10 (0-204)	0.03 1.7 (1.04-2.8)
1 year, %	66	71	49	
3 years, %	49	52	38	
5 years, %	42	46	29	
GRFS*, Median (range), days	207 (12-6453)	239 (21-6453)	169 (12-5738)	0.2 1.3 (0.8-2)
100 days, %	81	82	70	
200 days, %	52	57	34	
1 year, %	38	41	30	
3 years, %	20	21	16	
5 years, %	16	16	16	
Documented death at last follow up, n (%)	68 (49)	46 (44)	22 (64)	0.8
Non-relapse related	39 (63)	28 (64)	11 (61)	
Relapse related	23 (37)	16 (36)	7 (39)	

GRFS: graft versus host disease-free relapse-free survival.

*GRFS: absence of grade 3 or 4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death.